Welcome to our dedicated page for Clene SEC filings (Ticker: CLNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clene Inc. filings document regulatory, financing, governance and operating disclosures for a late clinical-stage biopharmaceutical company focused on neurodegenerative diseases. Form 8-K reports cover CNM-Au8 clinical and regulatory communications, operating and financial results, securities purchase agreements, warrant terms and grant-related subaward agreements supporting ALS expanded access activity.
Proxy materials describe annual meeting proposals, director elections, auditor ratification and other shareholder voting matters. The filing record also addresses capital-structure changes, material agreements, Regulation FD disclosures, intellectual-property provisions tied to research funding, clinical and regulatory disclosures, and the role of Clene Nanomedicine Inc. in the company’s development programs.
Clene Inc. reported that Chief Science Officer Mark Mortenson received a grant of stock options covering 45,000 shares of common stock. The options have an exercise price of $5.53 per share and expire on June 10, 2036. According to the grant terms, 25% of the options vest on June 11, 2027, with the remaining shares vesting in 36 equal monthly installments starting July 11, 2027. This is a compensation-related award, not an open-market stock purchase or sale.
Clene Inc. reported that President and CEO Robert Dee Etherington received a grant of stock options covering 65,000 shares of common stock. The options have an exercise price of $5.53 per share and expire on June 10, 2036. According to the grant terms, 25% of the options vest on June 11, 2027, with the remaining shares vesting in 36 equal monthly installments starting on July 11, 2027 until fully vested. This is a compensation-related award rather than an open-market purchase or sale.
Clene Inc. reported that Chief Financial Officer Morgan R. Brown received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $5.53 per share and expire on June 10, 2036. They vest 25% on June 11, 2027, with the remaining shares vesting in 36 equal monthly installments beginning July 11, 2027. This is a compensation-related award rather than an open‑market share purchase or sale.
Clene Inc. amended its senior secured convertible promissory notes with AE Capital Limited, A Global Chorus Foundation, and Glenn and Shelina Way. The maturity date was extended to the earlier of August 13, 2027 or a change in control, and monthly principal and interest payments of $150,000 that were set to begin on September 13, 2026 will instead be paid in full at maturity.
Stockholders approved the Clene Inc. Amended 2020 Stock Plan, increasing the shares of common stock reserved for issuance by 1,000,000. At the May 21, 2026 annual meeting, they also elected three directors and approved the remaining proposals by wide margins, with one item receiving 7,737,513 votes in favor.
Clene Inc. director Vallerie McLaughlin received stock option awards as equity compensation. On May 21, 2026, she was granted options covering a total of 3,564 shares of common stock at an exercise price of $6.81 per share under the Clene Inc. Amended 2020 Stock Plan.
One option grant for 2,064 shares vests immediately, giving her the right to purchase those shares at the set price. A second option grant for 1,500 shares vests in 12 equal monthly installments on the 21st of each month starting June 21, 2026, extending through the following year. Both option series expire on May 20, 2036 if not exercised.
Clene Inc. director Arjun JJ Desai received new stock option awards. On May 21, 2026, he was granted options for 2,158 and 1,500 shares of common stock at an exercise price of $6.81 per share under the Amended 2020 Stock Plan. The 2,158-share option vests immediately, while the 1,500-share option vests in 12 equal monthly installments starting on June 21, 2026. These are compensation-related grants with no open-market purchases or sales reported.
Clene Inc. director Alison Mosca reported receiving two grants of stock options as part of her compensation. One grant covers 2,861 options for common stock at an exercise price of $6.81 per share and vests immediately. A second grant covers 1,500 options at the same $6.81 exercise price and vests in 12 equal monthly installments on the 21st of each month beginning June 21, 2026. Both option awards expire on May 20, 2036, and represent equity-based awards rather than open-market share purchases or sales.
Clene Inc. director David J. Matlin reported receiving two stock option awards on May 21, 2026, totaling 5,159 options for common stock at an exercise price of $6.81 per share. One grant for 3,659 options vests immediately, while a 1,500-option grant vests in 12 equal monthly installments beginning on June 21, 2026. Both option awards expire on May 20, 2036 and represent equity compensation, with no open-market share purchases or sales reported.
Clene Inc. director Shalom Jacobovitz received two stock option awards as equity compensation. One option covers 2,791 shares of common stock at an exercise price of $6.81 per share and vests immediately. The second option covers 1,500 shares at the same exercise price and vests in 12 equal monthly installments starting on June 21, 2026.
These awards are structured as derivative securities that can be exercised into common stock before their expiration on May 20, 2036, and reflect routine compensation rather than open-market buying or selling.
Clene Inc. director Matthew Kiernan reported receiving two stock option awards as equity compensation. He was granted options on 1,876 and 1,500 shares of common stock, each with an exercise price of $6.81 per share, expiring on May 20, 2036.
The 1,876-share option vests immediately, while the 1,500-share option vests in 12 equal monthly installments starting on June 21, 2026. These are grants/awards, not open‑market purchases or sales.